HusCompagniet AS (HUSCO)
Copenhagen Exchange · Denmark · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 24.70 |
|---|---|
| 52-week range | 23.70 – 46.50 |
| Return, 1 month / 3 months | −10.8% / −22.8% |
| Return, 1 year / 3 years | −46.1% / −39.3% |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 29.4% |
| Worst drawdown (1 year) | -47.6% |
| Average daily value traded | 0.37M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
HusCompagniet is a Danish housebuilder that designs and constructs detached single-family homes for private customers. It offers a range of standard house types, often built from prefabricated elements, and guides buyers through choosing a design, customising it and having the home erected on their own plot. The company works through local sales offices and its own construction teams, and it is based in Denmark, where most of its customers are found.
On this site HusCompagniet AS appears as a stock on the Copenhagen Exchange (Denmark), code HUSCO, with prices in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
HusCompagniet AS (HUSCO) trades on the Copenhagen Exchange in Denmark. It last closed at DKK 24.70 on 23 October 2026.
Its price-based Market X-Ray is 22 out of 100 (a weak price profile), ranking 143 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 46.1% and over the last three months it fell 22.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Copenhagen Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 11 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -24.2% | ||
| From 52-week high | -46.1% | ||
| Momentum | 6 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -22.8% | ||
| 6-month return | -26.3% | ||
| 12-month return, skipping the last month | -39.5% | ||
| Stability (higher is calmer) | 36 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -47.6% | ||
| Liquidity | 46 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.37M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.5% |
|---|---|
| 1 month | −10.8% |
| 3 months | −22.8% |
| 6 months | −26.3% |
| 1 year | −46.1% |
| 3 years | −39.3% |
| 5 years | −78.4% |
Signals
| 50-day / 200-day average | 28.94 / 32.57 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 1.02 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Apr 2022 | DKK 7.3500 |
| 13 Apr 2021 | DKK 3.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Copenhagen Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.